SCHEMBL25964378

SCHEMBL25964378

CC(=O)Nc1nc2c(ncn2C(C)(C)C)c(=O)[nH]1

nearest known ligand 0.55

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 1/20 0.55
TSHR P16473 1/20 0.55
KMT2A Q03164 1/20 0.55
KDM4E B2RXH2 1/20 0.49
GAA P10253 1/20 0.49
TAS1R3 Q7RTX0 1/20 0.47
TAS1R1 Q7RTX1 1/20 0.47
GDA Q9Y2T3 1/20 0.45
ALDH1A1 P00352 2/20 0.41
HPGD P15428 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
ADORA3 P0DMS8 1/20 0.39
FGFR1 P11362 1/20 0.38
FGFR2 P21802 1/20 0.38
POLB P06746 1/20 0.38
ALOX15 P16050 1/20 0.38
TDP1 Q9NUW8 1/20 0.38
LMNA P02545 1/20 0.37
TK1 P04183 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18349588 0.86 KDM4E (0.46) MEN1TSHRKMT2AKDM4EGAA
SCHEMBL14725444 0.83 PI4KA (0.39) MEN1TSHRKMT2ATK1
SCHEMBL26200092 0.83 MEN1 (0.42) MEN1TSHRKMT2AKDM4EGAA
SCHEMBL24922819 0.82 PI4KA (0.38) MEN1TSHRKMT2ATK1
SCHEMBL27929251 0.82 MEN1 (0.58) MEN1TSHRKMT2AKDM4EGAA
SCHEMBL2054820 0.81 MEN1 (0.57) MEN1TSHRKMT2AKDM4EGAA
SCHEMBL10047156 0.79 PI4KA (0.38) MEN1TSHRKMT2ATK1
SCHEMBL24767728 0.79 MEN1 (0.55) MEN1TSHRKMT2AKDM4EGAA
SCHEMBL26200096 0.79 NPC1 (0.51) MEN1TSHRKMT2AKDM4EGAA
SCHEMBL21654897 0.78 RAF1 (0.43) MEN1TSHRKMT2ASMN1; SMN2POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11873316-B2 Compositions and methods for phosphoramidite and oligonucleotide synthesis WAVE LIFE SCIENCES LTD. (SG) 2024-01-16 US disclosed
EP-4219516-A2 CHIRAL CONTROL Wave Life Sciences Ltd. (SG) 2023-08-02 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11873316-B2 Compositions and methods for phosphoramidite and oligonucleotide synthesis RNGTT, POLI, FBL MEN1 1976/4885TSHR 4477/4885KMT2A 756/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.